vimarsana.com

Latest Breaking News On - Nutritional impacts - Page 1 : vimarsana.com

Ziftomenib Granted Breakthrough Therapy Designation by FDA in R/R AML

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

United statesTroy wilsonAmerican cancer societyDrug administrationKura oncology incBreakthrough therapy designationKura oncologyTherapy designationOrphan drug designationNutritional impacts

AML Survivor Tells Patients Waiting for a Stem Cell Donor Don t Ever Give Up Hope

For Maggie Cambora, who received a diagnosis of acute myeloid leukemia in 2020, the third potential donor match was the connection that saved her life, she told CURE®.

United statesKatharina harfMaggie camboraRonald wardleighAmerican cancer societyColorado universityAfter stem cellWestern colorado universityNutritional impacts

vimarsana © 2020. All Rights Reserved.